Online inquiry

IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9676MR)

This product GTTS-WQ9676MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19&CD3E gene. The antibody can be applied in Acute lymphocytic leukemia (ALL), Follicular lymphoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001178098.2; NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930; 916
UniProt ID P15391; P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ9676MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6192MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ2459MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 181
GTTS-WQ14084MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ8285MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HM10560A
GTTS-WQ6659MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ529MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ12249MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ5261MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CB-6
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW